Literature DB >> 10522789

Management of symptomatic hypertrophic obstructive cardiomyopathy--long-term results after surgical therapy.

H D Schulte1, K Borisov, E Gams, H Gramsch-Zabel, B Lösse, B Schwartzkopff.   

Abstract

BACKGROUND: The natural history of Hypertrophic Obstructive Cardiomyopathy (HOCM), is well known from earlier investigations. The yearly death rate of medically or non-treated patients with HOCM is between 1.7% and 4%. After conservative management with beta-blockers and/or calcium antagonist, early improvement is followed in many patients by a symptomatic and clinical impairment, which today may lead to surgical or interventional treatment.
METHODS: From 1963 to 12/1998 a total of 519 patients were operated by transaortic subvalvular myectomy (TSM). The mean age was 49 +/- 11 years (range 3 months - 82 years) in 292 males and 227 females.
RESULTS: The early risk was related to the clinical class (NYHA) and the need for additional cardiac procedures during the same intervention. Total early mortality was 4.4% (n=23), in isolated myectomy 3.6% (n= 11). During the last 10 years it could be reduced to 1.9%. The first complete (100%) reinvestigation of 346 patients up to 26 years after surgery (1963-1991) demonstrated a disease-related mortality rate of 5.2% (n=20). The analysis of late deaths showed that disease-related lethal complications (sudden death, life-threatening arrhythmias, valve endocarditis, secondary LV dilatation) were relatively rare, the age-related death rate nearly followed the natural course because of other causes. The cumulative survival rate after 10 years was 88%, after 20-26 years 72%. The yearly disease-related death rate could be reduced to 0.6%. The long-lasting, symptomatic clinical improvement (NYHA I-II), and also the physical and mental capacity with enlargement of the acitivity radius and improvement of quality of life were remarkable. The positive effects of surgical enlargement of the LVOT could be confirmed in the meantime by hemodynamic, rhythmological, echocardiographic investigations as well as endurance tests.
CONCLUSION: We have examined the outcome of a large series of patients treated surgically for HOCM since 1963. The majority of patients were in NYHA class III and came to surgery after long-term medical, but finally insufficient, management. The perioperative risk could be reduced considerably during recent years, despite the advanced cardiomyopathy status. The long-term postoperative observation of the patients demonstrated an unexpectedly continuing good outcome. Therefore these results may serve as a standard for assessing the results after the less invasive alcohol-induced transcoronary ablation of septal hypertrophy.

Entities:  

Mesh:

Year:  1999        PMID: 10522789     DOI: 10.1055/s-2007-1013146

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  15 in total

Review 1.  Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment.

Authors:  Daniel L Jacoby; Eugene C DePasquale; William J McKenna
Journal:  CMAJ       Date:  2012-10-29       Impact factor: 8.262

2.  Is surgery the gold standard in the treatment of obstructive hypertrophic cardiomyopathy?

Authors:  Gennady Knyshov; Vasyl Lazoryshynets; Kostyantyn Rudenko; Borys Kravchuk; Vyacheslav Beshlyaga; Valery Zalevsky; Olga Rasputnyak; Bogdan Batsak
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-09-30

3.  Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: Systematic review and meta-analysis.

Authors:  Mohammed Osman; Babikir Kheiri; Khansa Osman; Mahmoud Barbarawi; Hani Alhamoud; Fahad Alqahtani; Mohamad Alkhouli
Journal:  Clin Cardiol       Date:  2018-11-29       Impact factor: 2.882

4.  Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography.

Authors:  Christian Sohns; Samuel Sossalla; Jan D Schmitto; Claudius Jacobshagen; Björn W Raab; Silvia Obenauer; Lars S Maier
Journal:  Clin Res Cardiol       Date:  2010-02-21       Impact factor: 5.460

5.  Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients.

Authors:  F H Gietzen; C J Leuner; L Obergassel; C Strunk-Mueller; H Kuhn
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

6.  Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.

Authors:  Horst Kuhn; Thorsten Lawrenz; Frank Lieder; Christian Leuner; Claudia Strunk-Mueller; Ludger Obergassel; Markus Bartelsmeier; Christoph Stellbrink
Journal:  Clin Res Cardiol       Date:  2007-12-10       Impact factor: 5.460

Review 7.  The "1st septal unit" in hypertrophic obstructive cardiomyopathy: a newly recognized anatomo-functional entity, identified during recent alcohol septal ablation experience.

Authors:  Paolo Angelini
Journal:  Tex Heart Inst J       Date:  2007

8.  Risk stratification for sudden cardiac death after septal myectomy.

Authors:  Richard D Rothman; Muhamad A Safiia; Patricia A Lowry; Theofanie Mela; Suhny Abbara; Caitlin O'Callaghan; Eugene J Mark; Gus J Vlahakes; Michael A Fifer
Journal:  J Cardiol Cases       Date:  2011-01-13

9.  Application of 3D printing in the surgical planning of hypertrophic obstructive cardiomyopathy and physician-patient communication: a preliminary study.

Authors:  Hong-Chang Guo; Yang Wang; Jiang Dai; Chang-Wei Ren; Jin-Hua Li; Yong-Qiang Lai
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

10.  Hypertrophic Cardiomyopathy in a Young Adult with RV Aneurysm: Report of a Rare Finding and Review of the Literature.

Authors:  Ahmed M Abdel-Razek; Leonard Y Lee; Robert Tozzi
Journal:  Heart Views       Date:  2011-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.